MIAMI, June 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced the successful completion of an investigator meeting for ELPIS II, the on-going Phase 2b clinical trial evaluating Lomecel-B™ as a potential adjunct treatment for Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric congenital heart birth defect. The investigator meeting was organized to discuss the progress to date and operational implementation of the clinical trial, inviting the principal investigator and site staff from premiere infant and children’s treatment institutions across the country. ELPIS II is on track to complete enrollment by the end of 2024.

Here is the original post:
Longeveron® Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B™ as a Potential...